Eli Lilly freezes salaries; Dr. Reddy's grows manufacturing; Pfizer spins off India animal health;

> This year Eli Lilly ($LLY) will freeze the salaries of most employees worldwide because of market challenges but did not say if there were manufacturing plant labor agreements that might exempt some employees from the penny-pinching. Story

> Generic drugmaker Dr. Reddy's Laboratories ($RDY), India's No. 2 drugmaker by sales, reports that its third-quarter global income from manufacturing services and pharmaceutical ingredients grew 12 percent to 5.56 billion rupees. Story

> Florida Biologix has said that its aseptic fill-and-finish facility for biopharmaceutical drug products meets European GMP requirements. Story

> The animal healthcare business of India's Pfizer Ltd. is being spun off from parent Pfizer ($PFE) for 4.4 billion rupees. Story

> OctoPlus, which develops and manufactures injectable pharmaceuticals, has signed a formulation development and manufacturing contract with Ferring Pharmaceuticals. Story

> Japan's Daiichi Sankyo, majority owner of troubled Indian generics maker Ranbaxy Laboratories ($RANBAXY.NS), is reportedly in talks to buy several smaller Indian drug companies. Story

> A lawsuit filed in New York alleges that Pfizer and Ranbaxy Laboratories schemed to delay generic Lipitor. Story

> GlaxoSmithKline ($GSK) will invest $65 million to expand its manufacturing and new drug development facilities near Melbourne, Australia. Story


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.